|
Books > Medicine > Clinical & internal medicine > Haematology
This book surveys healthy and diseased vascular systems in a
multitude of model organisms and systems. It explores a plethora of
functions, characteristics, and pathologies of the vascular system
such as angiogenesis, fibroblast growth factor signaling,
lymphangiogenesis, junctional signaling, the extracellular matrix,
vascular permeability, leukocyte extravasation, axon guidance
factors, the angiopoietin system, and chronic obstructive lung
disease. Following a preface from leading researcher Dr. Holger
Gerhardt, the text is divided into three sections- the first
examining the development of the vascular system in a variety of
contexts, the second delving into its homeostatic characteristics,
and the third discussing its pathophysiologies. The sixteen
chapters, which represent international clinical and research
perspectives, highlight the importance of molecular and signaling
pathways for translational basic science and clinical medicine.
Additionally, the text explores new and exciting fields in vascular
biology research. Comprehensive in both content and approach,
Vascular Signaling in Health and Disease is ideal for graduate
students, researchers, and clinicians interested in vascular
biology, pneumology, and molecular biology.
This book provides a state-of-the-art approach to the molecular
basis of hematologic diseases and its translation into improved
diagnostics and novel therapeutic strategies. Several
representative hemato-oncologic malignancies are analyzed in
detail: acute lymphoblastic leukemia, acute myeloid leukemia,
B-cell Non-Hodgkin lymphomas, multiple myeloma, chronic lymphocytic
leukemia, chronic myeloid leukemia, myelodysplastic syndromes, and
myeloproliferative neoplasms. Experts in the field describe the
molecular methods applied for modern diagnostics and therapies,
such as hematopoietic stem cell transplantation, donor recipient
matching, banking of biological material, analyses of
post-transplant chimerism, and minimal residual disease monitoring.
The volume concludes with an extensive section comprising thorough
step-by-step protocols of molecular techniques in hematology, all
of them validated in the authors' own laboratories.
This handbook is an in-depth and comprehensive guide to the
pathophysiology, diagnosis, staging, treatment and management of
patients with multiple myeloma. The Handbook was commissioned to
address an unmet need for a book of this kind in the myeloma field
and to provide busy healthcare professionals with an informative
and educational review of the current and emerging treatment
recommendations for multiple myeloma. Myeloma is a type of bone
marrow cancer arising from plasma cells and is the second most
common form of bone marrow cancer, but represents just 1% of all
cancers. The causes of myeloma are not fully understood but it is
thought to be caused by an interaction of both genetic and
environmental factors. This Handbook discusses these issues as well
the latest developments in the field and will be an invaluable
source of topical information for all healthcare professionals with
an interest in multiple myeloma.
Multiple myeloma is a plasma cell malignancy characterized by
complex heterogenous cytogenetic abnormalities that accounts for
1.4% of all cancers, and approximately 10% of hematologic
malignancies. The clinical manifestations of multiple myeloma
include lytic bone lesions, cytopenia, hypercalcemia, renal
dysfunction, hyperviscosity of the blood, immunodeficiency, and
peripheral neuropathy. Based on the clinical and genetic data,
probably all cases of multiple myeloma arise from an asymptomatic
monoclonal gammopathy of unknown significance. The exact mechanism
of the transition from MGUS to overt multiple myeloma is still not
well understood. Recent oncogenomic studies have further advanced
our understanding of the molecular pathogenesis of multiple
myeloma. This book will give a comprehensive overview of the
genetic and molecular epidemiology of multiple myeloma in order to
get a more refined and conclusive understanding of this disease.
Developed specifically for student nurses and based on the author's
over thirty years of teaching experience, Interpreting Arterial
Blood Gases the Easy Way teaches students a step-by-step method for
interpreting blood gases and helps them learn how to apply the
interpretations. The booklet is divided into two parts. Part I
teaches students to differentiate between acidic and alkaline
states, identify respiratory or metabolic changes in blood gases,
and recognize compensated, partially compensated, and uncompensated
states. In Part II students apply what they have learned in order
to recognize signs and symptoms of abnormal blood gases, identify
appropriate interventions, and understand the meaning and
significance of specific oxygenation levels. Clear and
well-organized, the material features quizzes for self-evaluation,
critical thinking questions, and tips that may assist with the
National Council Licensure Examination. Knowledge of basic
physiology and acid-base balance is recommended before using the
booklet, but the information is also reviewed. Interpreting
Arterial Blood Gases the Easy Way is an excellent choice for
nursing programs. It can also be used in training respiratory
therapists and emergency medical technicians.
Mantle cell lymphoma (MCL) is a subtype of Non-Hodgkin's Lymphoma
(NHL) with varying clinical presentations, ranging from indolent
disease to highly aggressive symptoms. MCL represents approximately
3-10% of non-Hodgkin lymphomas, and has increased in incidence over
the past several decades. The majority of patients respond to
initial therapy, but remission duration is typically short. This
book discusses the clinical characteristics of mantle cell
lymphoma, as well as its prevalence and examines several treatment
options available.
This book provides clinical practitioners and the research
community with detailed information on the diagnosis, prognosis,
and treatment of non-Hodgkin lymphoma, taking into account the
significant growth in knowledge including multiple therapeutic
advances that have been achieved over the past 5-10 years. The work
is subdivided into epidemiology, pathogenesis, pathology, imaging,
and therapy of the non-Hodgkin lymphomas. The full range of
therapeutic options are examined according to the major subtypes of
non-Hodgkin lymphoma and the most up-to-date information is
provided on current standard treatment options, including stem cell
transplantation as well as new cutting-edge therapeutics.
Sickle Cell Disease is the most common genetic disease world wide
and in the UK. It has marked geographical variation in its
distribution in the UK, with a concentration in London and other
major conurbations (Birmingham and Manchester). In these areas,
specialist centres have become established offering expert, up to
date care for both inpatients and out patients with Sickle Cell
Disease. Although patient numbers are increasing outside these
areas, the expertise of health professionals can be patchy. This
book aims to provide a user friendly, accessible resource for areas
with smaller numbers of patients, to allow them to provide
equitable care with the larger well established centres. Sickle
Cell Disease can be associated with acute life threatening
complications, when clear, easily available advice is needed, and
with chronic long term complications which may need liaison with
other health professionals. Clear treatment protocols for all the
common complications of sickle cell disease, are outlined here,
with summaries of key evidence and references.
John John is a healthy 14 year old, 6ft tall boy that always had a
smile on his face. He is an excellent student in school and is well
liked by his peers and teachers. Johnathan is like any other kid
and enjoys playing games, listening to music, and getting on
Facebook to communicate with those near and far. He also loves to
play basketball and was recruited by his gym teacher to play for
the school team. Then out of the blue, John John became deathly
ill. Our whole world changed after then.
Myelodysplastic syndromes (MDS) are the most common hematological
malignancies involving mostly the elderly population. The major
morbidity relates to patients' symptomatic cytopenias.MDS was
previously named as "preleukemia " or " smoldering leukemia" as the
lack of terminal cells in MDS and because about 25% of all cases
progresses into acute myeloid leukemia. According to various
reports the annual incidence of MDS ranges widely from 2-12 per
100.000, increasing to 30-50 cases per 100.000 among persons aged
70 or older. It is believed that the true incidence of MDS have
been underestimated however it seems to be comparable to that for
multiple myeloma and chronic lymphocytic leukemia. In the past
decade much progress had been made; we know more on the disease
pathology, there is more emphasis on the care and more targeted
therapy had been invested. Athors provide updated knowledge in this
book on all clinically important aspects of the disease. Hot topics
of our days are discussed in chapters by outstanding and well known
scientists from all over the world. We would offer this product
both for medical students and postgraduates as well as for all who
are interested in this very exciting and fast progressing field of
hematology. With this work authors should call attention on the
disease for decision makers in healt care systems as well.
In this second edition of Disorders of Thrombosis and Hemostasis in
Pregnancy - A Guide to Management the content has been thoroughly
updated, with a particular focus on strengthening the management
sections to ensure that advice on management represents state of
the art.
Infections are among the most frequent complications in patients
with hematological malignancies and in those undergoing high-dose
chemotherapy and autologous hematopoietic stem cell
transplantation. A profound knowledge on the epidemiology,
diagnostic approaches, treatment modalities and prophylactic
strategies is essential for the clinical management of these
complications in patients who are often severely immunocompromised
owing to their underlying diseases and in particular, the intensive
myelosuppressive chemo and immunotherapy. This textbook provides a
clinically oriented, compact and up-to-date overview on infections
in hematology patients and their management. The typical pathogens
to be considered in different subgroups of patients are identified
and further aspects of the microbiological background are explored.
Clinical, imaging, and laboratory-based diagnostic techniques are
discussed and therapeutic strategies appropriate to different
situations are then presented, with due attention to the pitfalls,
toxicities and interactions that can arise during antimicrobial
treatment. Strategies to prevent infection are also outlined,
encompassing antimicrobial prophylaxis, isolation procedures,
hospital hygiene, protective immunization and the use of
hematopoietic growth factors.
The extravasation of cytotoxic agents can result in severe local
tissue damage and medical emergencies during tumour therapy. This
revised compendium is intended to help clinicians assess any
situation speedily and with certainty. The general section of the
book includes topics such as predisposition, prevention, type of
harm, general measures in handling extravasated drugs, specific
antidotes, and documentation. In the 2nd edition, the scientific
information contained in the general section and relating to the
actual substances has been updated. The substance specific part of
the book includes detailed instructions on handling more than 50
cytotoxic drugs, to initiate targeted measures. Templates for an
extravasation set, overview tables, documentation sheets, and
patient information, as we as a CD-ROM are included to support
clinical practice. The book is the outcome of a consensus of an
interdisciplinary working group that has collected and
systematically reviewed all published literature on the topic.
The blood system is multi-scale, from the organism to the organs to
cells to intracellular signaling pathways to macromolecule
interactions. Blood consists of circulating cells, cellular
fragments (platelets and microparticles), and plasma
macromolecules. Blood cells and their fragments result from a
highly-ordered process, hematopoiesis. Definitive hematopoiesis
occurs in the bone marrow, where pluripotential stem cells give
rise to multiple lineages of highly specialized cells.
Highly-productive and continuously regenerative, hematopoiesis
requires a microenvironment of mesenchymal cells and blood vessels.
A Systems Biology Approach to Blood is divided into three main
sections: basic components, physiological processes, and clinical
applications. Using blood as a window, one can study health and
disease through this unique tool box with reactive biological
fluids that mirrors the prevailing hemodynamics of the vessel walls
and the various blood cell types. Many blood diseases, rare and
common can and have been exploited using systems biology approaches
with successful results and therefore ideal models for systems
medicine. More importantly, hematopoiesis offers one of the best
studied systems with insight into stem cell biology, cellular
interaction, development; linage programing and reprograming that
are every day influenced by the most mature and understood
regulatory networks.
In the last decade, there has been a remarkable explosion of
knowledge in hematologic cancer from basic molecular biology and
pathology to clinical therapy. This has led to many new advance and
insights in the understanding of pathobiology of malignant
hematology. New knowledge of disease molecular pathology,
cytogenetic, epigenetic and genomic alterations have provided new
strategies to attack and eradicate tumor cells at molecular level
and significantly impacted our current therapeutics for
hematological malignancies. The recent and ongoing rapid expansion
of knowledge in this area has become extensive, dynamic and diffuse
over the literature and research publications. This has led to the
need to capture and compile the new and current information about
hematologic cancer with special emphasis on translation from
molecular pathobiology to targeted therapeutics. In this book
experts from around the world share their thoughts and knowledge
about the pathobiology of hematologic cancer, as well as their view
on current treatment approaches and future development in these
malignant hematologic diseases. This book is well suited for
hematology residents, fellows and hematology-oncology physicians,
hematopathologist as well as basic research scientist in the area
of hematologic malignancies.
|
|